(Created page with "'''Landmark Papers/Studies in Dorsal Root Ganglion (DRG) Spinal Cord Stimulation:''' <big>1. Esposito MF, Malayil R, Hanes M, Deer T. Unique characteristics of the dorsal root ganglion as a target for neuromodulation. Pain Med. 2019;20(Suppl 1):S23–S30. doi: 10.1093/pm/pnz012 a. Details advantages of DRG over traditional SCS including less energy requirement, more focused/posture-independent stimulation, reduced parasthesias, improved outcomes 2. L...")
Tag: 2017 source edit
 
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
'''Landmark Papers/Studies in Dorsal Root Ganglion (DRG) Spinal Cord Stimulation:'''
[[File:Landmark Papers in Traditional Spinal Cord Stimulation.docx|thumb]]
<big>1.      Esposito MF, Malayil R, Hanes M, Deer T. Unique characteristics of the dorsal root ganglion as a target for neuromodulation. Pain Med. 2019;20(Suppl 1):S23–S30. doi: 10.1093/pm/pnz012
a.      Details advantages of DRG over traditional SCS including less energy requirement, more focused/posture-independent stimulation, reduced parasthesias, improved outcomes
2.      Liem L, Russo M, Huygen FJ, Van Buyten JP, Smet I, Verrills P, Cousins M, Brooker C, Levy R, Deer T, Kramer J. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain. Neuromodulation. 2015 Jan;18(1):41-8; discussion 48-9. doi: 10.1111/ner.12228.
a.      Multicenter study showing DRG-SCS to be comparable to traditional SCS in terms of pain relief with benefit of being able to target regions sometimes difficult to target with traditional SCS and to maintain coverage over time
                                                              i.    Led to European Union and Australia approving DRG in 2011
3.      ACCURATE Study; Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669–681. doi: 10.1097/j.pain.0000000000000814.
a.      Showed superiority in DRG versus traditional SCS for pain reduction at 3 and 12 months as well as greater improvements in quality of life and psychological disposition with more targeted therapy (less postural variation); In CRPS/causalgia patients
                                                              i.    Led to FDA approving DRG in 2016
4.      Eldabe S, Espinet A, Wahlstedt A, Kang P, Liem L, Patel NK, Vesper J, Kimber A, Cusack W, Kramer J. Retrospective Case Series on the Treatment of Painful Diabetic Peripheral Neuropathy With Dorsal Root Ganglion Stimulation. Neuromodulation. 2018 Dec;21(8):787-792. doi: 10.1111/ner.12767.
a.      Evidence for the use of DRG for painful diabetic neuropathy
5.      Hunter CW, Yang A. Dorsal Root Ganglion Stimulation for Chronic Pelvic Pain: A Case Series and Technical Report on a Novel Lead Configuration. Neuromodulation. 2019 Jan;22(1):87-95. doi: 10.1111/ner.12801.
a.      Evidence supporting DRG in chronic pelvic pain, L1/S2 lead placement</big>

Latest revision as of 11:34, 7 March 2024